Changsha, China – May 22, 2025– Hunan Huateng Pharmaceutical Co., Ltd., a leading global supplier of PEG derivatives and pharmaceutical intermediates, is proud to offer high-purity N-Benzylhydroxylamine Hydrochloride (CAS 29601-98-7) to researchers and pharmaceutical ...Learn More

Changsha, China – 18 March 2025 – Hunan Huateng Pharmaceutical Co., Ltd., a global leader in PEG derivatives and CDMO services for APIs and intermediates, is pleased to announce its participation in CPHI Japan 2025. The company will exhibit its comprehensive product lines and ...Learn More

Changsha, China, July 22, 2024 - Huateng Pharma, a global leader in PEG derivatives and a premier CDMO for APIs and intermediates, is excited to announce the launch of its latest product, Y-Shape PEG NHS. This cutting-edge Succinimidyl Carboxymethyl Ester branched 2ARM PEG offers ...Learn More

Shanghai, China – June 14, 2024 – Hunan Huateng Pharmaceutical Co., Ltd., a global leader in the production of PEG derivatives and Contract Development and Manufacturing Organization (CDMO) services for Active Pharmaceutical Ingredients (APIs) and intermediates, is excited to ...Learn More

Hunan Huateng Pharmaceutical Co., Ltd, a global leader in PEG derivatives and Contract Development and Manufacturing Organization (CDMO) services, cordially invites you to visit our booth at CPhI Japan 2024, held from April 17th to 19th at Tokyo Big Sight, Tokyo, Japan. Event ...Learn More